HLB Pharmaceutical's Cumulative Q3 Revenue Up 34% to KRW 190.4 Billion

HLB Pharmaceutical's consolidated revenue for the first three quarters of this year totaled KRW 190.4 billion, up 34.0% from the same period last year.

HLB Pharmaceutical said on November 13 that its cumulative operating profit rose 707.5% year over year to KRW 1.85 billion. In the third quarter alone, revenue came to KRW 62.5 billion and operating profit to KRW 850 million.

By business segment, cumulative third-quarter revenue from prescription drugs (ETC) rose 11.5% year over year to KRW 104.6 billion. Contract manufacturing (CMO) revenue increased 9.0% to KRW 5.26 billion, while consumer healthcare revenue grew 40.3% to KRW 16.4 billion.

Shinhwa Advance, HLB Pharmaceutical's pharmaceutical distribution subsidiary, also continued to grow its revenue after joining the group. Its cumulative revenue for the first three quarters was KRW 65.987 billion, up 18.0% from KRW 55.916 billion in the same period last year.

HLB Pharmaceutical plans to continue expanding revenue in key businesses, including prescription drugs and consumer healthcare, while broadening its growth base by strengthening its production and sales competitiveness.

An HLB Pharmaceutical official said, "We are continuing to grow revenue through increases in our key business segments. We will continue to build a stable foundation for growth by strengthening our production competitiveness and improving profitability."

This content was produced with the assistance of AI translation services.